VC-backed Aprea Therapeutics sets IPO pricing terms
Boston and Stockholm-based Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, has priced its IPO of 5 million shares between $14 and $16 per share. Aprea is backed by Redmile Group, Rock Springs Capital, 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB.
23 September 2019•2 mins read
